Method of treating and/or diagnosing soft tissue tumors

Abstract

A method for therapeutic and/or diagnostic treatment of soft tumor carcinoma in mammals using certain metals or particle-emitting radionuclides complexed with hydroxyethylethylenediaminetriacetic acid is described.

What is claimed is: 
     
       1. A method for the therapeutic and/or diagnostic treatment of a mammal having a non-calcific tissue tumor which comprises administering to said mammal an effective amount of a composition comprising: (1) a complex which comprises a ligand and a metal wherein the ligand is hydroxyethylethylenediaminetriacetic acid or a pharmaceutically acceptable salt thereof and wherein the metal ion is  153  Sm,  166  Ho,  90  Y,  165  Dy,  159  Gd,  177  Lu,  111  In,  115m  In,  175  Yb,  47  Sc,  52  Fe,  72  Ga,  67  Ga, or  68  Ga and the ligand to metal molar ratio is 100:1 to about 500:1, and (2) a physiologically acceptable liquid carrier. 
     
     
       2. A method of claim 1 for therapeutic treatment. 
     
     
       3. The method of claim 2 wherein the metal is  166  Ho,  90  Y,  175  Yb,  165  Dy,  115m  In,  52  Fe, or  72  Ga. 
     
     
       4. A method of claim 1 for diagnostic treatment. 
     
     
       5. The method of claim 4 wherein the metal is  111  In,  67  Ga,  68  Ga. 
     
     
       6. The method of claim 1 for therapeutic and diagnostic treatment. 
     
     
       7. The method of claim 6 wherein the metal is  153  Sm,  177  Lu,  175  Yb,  159  Gd, or  47  Sc. 
     
     
       8. The method of claim 7 wherein the metal is  153  Sm. 
     
     
       9. A method of claim 1 wherein the ligand to metal molar ratio is from 250:1 to about 300:1. 
     
     
       10. A method of claim 1 wherein the metal used is in the no carrier added form. 
     
     
       11. A method of claim 10 wherein the ligand to metal molar ratio is about 5×10 7  :1. 
     
     
       12. The method of claim 1 wherein the physiologically acceptable liquid carrier is water and the resulting solution is adjusted to have a pH of about 7 to about 8. 
     
     
       13. The method of claim 1 wherein the ligand is in the form of its sodium salt. 
     
     
       14. The method of claim 1 wherein the composition administered to a mammal contains 2 or more different radioisotopes.